Core Insights - The company, Ascentage Pharma, is focused on addressing unmet clinical needs in oncology and has established a strong positioning in global innovation through its deep expertise in apoptosis pathways and related drug development [1][2] Pipeline and Product Development - Ascentage Pharma has developed a rich pipeline of innovative drugs, including the next-generation BTK-targeted protein degrader APG-3288, which is a highlight of its global innovation strategy [2] - The company has successfully launched two major Class 1 new drugs: Nilotinib, approved in 2021 as China's first third-generation BCR-ABL inhibitor, and Lisenglitazone, set to be approved in July 2025 as China's first domestically developed Bcl-2 inhibitor [2][3] - Lisenglitazone is expected to break the nine-year monopoly of AbbVie’s Bcl-2 inhibitor Venetoclax, with a broader approval scope for chronic lymphocytic leukemia (CLL) patients compared to Venetoclax [3] Research and Development Strategy - The company adheres to two core principles: focusing on unmet clinical needs and ensuring true innovation, which have been pivotal in the successful launch of its core products [3] - Ascentage Pharma employs a rigorous pipeline selection process based on three criteria: addressing unmet clinical needs, emphasizing disease biology research, and ensuring drug viability [4] Global Development and Commercialization - The company is conducting over 40 clinical trials globally, including three global Phase III trials for Nilotinib, which have received approval from the FDA and EMA [5][6] - Ascentage Pharma has established significant partnerships, including a major collaboration with Takeda for Nilotinib, which has provided substantial financial benefits and enhanced brand recognition [6] - The company plans to list on NASDAQ in January 2025, becoming the first biopharmaceutical company to achieve dual listing in Hong Kong and the U.S., which is crucial for attracting international investors [7] Financial Performance and Market Strategy - In the first half of 2025, Ascentage Pharma reported revenues of 234 million yuan, with Nilotinib sales reaching 217 million yuan, a 93% increase year-on-year due to its inclusion in the national medical insurance directory [8] - The company has developed a dual approach for commercializing its products, partnering with established firms for initial market entry while building its own commercialization team for long-term growth [8][9] - Following the approval of Lisenglitazone, the company quickly signed agreements with major pharmaceutical distributors to facilitate rapid market entry and patient access [9] Future Outlook - Ascentage Pharma aims to expand its commercialization team significantly, from over 200 to 400 members by 2026, to enhance market presence and patient accessibility [9] - The company plans to accelerate multiple key global Phase III clinical projects and push for the inclusion of Lisenglitazone in the medical insurance directory, continuing its global innovation strategy [9]
亚盛医药董事长杨大俊：以持续创新筑根基，全球布局启新程